Evidence map›Paper›PMID 34990908›Full record

ArticleTranslational oncology2022

Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice.

Susumu Ishiguro, Deepa Upreti, Molly Bassette, E R Azhagiya Singam, Ravindra Thakkar, Mayme Loyd, Makoto Inui, Jeffrey Comer, Masaaki Tamura

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Susumu IshiguroDepartments of Anatomy and Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA. Electronic address: isusumu@vet.ksu.edu.
Deepa UpretiDepartments of Anatomy and Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA. Electronic address: deepa07@vet.ksu.edu.
Molly BassetteDepartments of Anatomy and Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA; Department of Pathology, University of California, San Francisco, CA 94143, USA. Electronic address: Molly.Bassette@ucsf.edu.
E R Azhagiya SingamDepartments of Anatomy and Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA; Molecular Graphics and Computation Facility, College of Chemistry, University of California, Berkeley, CA 94720, USA. Electronic address: eazhagiy@berkeley.edu.
Ravindra ThakkarDepartments of Anatomy and Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA. Electronic address: ravithakkar@vet.ksu.edu.
Mayme LoydDepartments of Anatomy and Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA. Electronic address: mkloyd@ksu.edu.
Makoto InuiDepartments of Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan. Electronic address: minui@yamaguchi-u.ac.jp.
Jeffrey ComerDepartments of Anatomy and Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA. Electronic address: jeffcomer@ksu.edu.
Masaaki TamuraDepartments of Anatomy and Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA. Electronic address: mtamura@vet.ksu.edu.
Kansas State University · USUniversity of California, Berkeley · USUniversity of California, San Francisco · USYamaguchi University · JP

Funding

Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Douglas E Wright · 2012 to 2026
$63.0M
Cancer-targeted local pulmonary immunotherapy with PD-L1 inhibitory peptide secretory genes for the treatment of lung cancerR15CA219919 · NCI · KANSAS STATE UNIVERSITY · PI COMER, JEFFREY ROBERT, TAMURA, MASAAKI · 2017 to 2017
$380k
NCI NIH HHS R15 CA219919NIGMS NIH HHS P20 GM103418
6 · The paper itself

Abstract

A novel peptide that interferes with the PD-1/PD-L1 immune checkpoint pathway, termed PD-L1 inhibitory peptide 3 (PD-L1ip3), was computationally designed, experimentally validated for its specific binding to PD-L1, and evaluated for its antitumor effects in cell culture and in a mouse colon carcinoma syngeneic murine model. In several cell culture studies, direct treatment with PD-L1ip3, but not a similar peptide with a scrambled sequence, substantially increased death of CT26 colon carcinoma cells when co-cultured with murine CD8

Indexed as

AdenovirusColon cancerPD-L1 blockade therapyPD-L1 inhibitory peptidePD-L1 inhibitory peptide secretory gene

Identifiers

PMID34990908
PMCPMC8741604
OpenAlexW4205942832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.